Biocon Ltd
Company Profile
Business description
Biocon Ltd is a biopharmaceutical company engaged in the manufacture of biotechnology products, active pharmaceutical ingredients, and formulations, including biosimilar drugs for diabetes, oncology, autoimmune diseases, and ophthalmology, as well as research services. The Company focuses on the core therapeutic areas of diabetes, oncology and immunology. Its segments are Generics, Biosimilars, and CRDMO, with Biosimilars generating the maximum revenue. The Company also complies with Extended Producer Responsibility (EPR) obligations by integrating EPR considerations into packaging design, procurement practices, and vendor engagement processes. The Company generates a majority of its revenue from customers located in India, and the rest from Brazil, Singapore, and the rest of the world.
Contact
20th KM, Hosur Road
Electronics City
BengaluruKA560100
INDT: +91 8028082808
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9,811
Stocks News & Analysis
stocks
ASX energy share undervalued ahead of earnings
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
stocks
This onetime AI market darling is now surprisingly undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.40 | 69.70 | 0.77% |
| CAC 40 | 8,613.82 | 104.18 | 1.22% |
| DAX 40 | 26,001.31 | 372.07 | 1.45% |
| Dow JONES (US) | 52,988.47 | 503.44 | 0.96% |
| FTSE 100 | 10,857.70 | 10.35 | -0.10% |
| HKSE | 26,009.40 | 124.97 | 0.48% |
| NASDAQ | 25,893.77 | 519.91 | 2.05% |
| Nikkei 225 | 63,754.90 | 607.12 | -0.94% |
| NZX 50 Index | 13,774.93 | 75.65 | 0.55% |
| S&P 500 | 7,588.95 | 99.23 | 1.32% |
| S&P/ASX 200 | 9,019.30 | 70.30 | 0.79% |
| SSE Composite Index | 3,809.66 | 22.60 | -0.59% |